DEF: Certara Schedules 2026 Annual Meeting, Announces CEO Transition

Certara, Inc. has announced its 2026 Annual Meeting of Stockholders, to be held virtually on May 14, 2026, and highlighted a leadership transition with Jon Resnick succeeding William Feehery as CEO.

Summary

• Certara, Inc. is holding its 2026 Annual Meeting of Stockholders virtually on May 14, 2026, at 9:00 a.m. Eastern Time.
• Stockholders can attend, vote, and submit questions online via a webcast link.
• Key proposals for the meeting include the election of three Class III directors: Arjun Bedi, Stephen McLean, and Jon Resnick.
• The appointment of RSM US LLP as the independent registered public accounting firm for fiscal year 2026 will be ratified.
• A non-binding advisory vote will be held to approve the compensation of named executive officers for the most recently completed fiscal year.
• Jon Resnick officially succeeded William Feehery as Chief Executive Officer on January 1, 2026.
• The company's stock is listed on The Nasdaq Stock Market under the ticker symbol CERT.
• Certara is a global leader in biosimulation software and technology-enabled services for drug development.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as neutral to slightly positive, primarily due to the clear communication regarding the annual meeting and leadership transition, with no significant negative financial or operational disclosures.

Positives

• Smooth CEO transition with Jon Resnick taking over from William Feehery.
• Virtual annual meeting format allows for broad stockholder participation.
• Strong governance practices are in place, including independent board committees and a clawback policy.
• Stock ownership guidelines are in place for directors and executives to align interests with stockholders.
• The company has a robust risk oversight structure managed by the Audit Committee.

Negatives

• Two directors, Rosemary Crane and Cynthia Collins, will conclude their service on the Board following the election of new Class III directors.
• William F. Feehery, the former CEO, received severance and consulting fees totaling $6,491,387 in 2025.

Risks

• Potential for broker non-votes on non-routine matters (director elections, executive compensation) which do not count as votes cast.
• The company's insider trading policy prohibits hedging, margin accounts, and pledging of securities without pre-clearance.
• The clawback policy allows for recovery of incentive-based compensation in the event of an accounting restatement.

Future Outlook

The filing primarily concerns the upcoming annual meeting and director elections, with no specific forward-looking financial guidance provided. The company's business is centered around biosimulation software and services for drug development.

Management Comments

• "On behalf of the Board of Directors and management of Certara, Inc., I am pleased to invite you to attend our 2026 Annual Meeting of Stockholders..."
• "This years meeting will be conducted virtually, allowing you to attend, vote your shares, and submit questions from any location with internet access."
• "2026 marks a year of an important leadership transition for Certara. Effective January 1, 2026, I succeeded William Feehery as Chief Executive Officer."
• "On behalf of the Board, I would like to thank Bill for his leadership and many contributions to Certara."
• "Whether or not you plan to attend the virtual meeting, your vote is important."

Industry Context

StockSavvy.ai notes that Certara operates in the critical biopharmaceutical services sector, providing essential tools for drug development. The company's focus on biosimulation aligns with the industry's increasing need for efficiency and data-driven decision-making in R&D.

Management Changes

Corporate Governance

Related Party Transactions

• Arsenal Capital Partners has rights to nominate directors to the Board under a Stockholders Agreement.
• Arsenal Capital Partners is subject to a letter agreement restricting the transfer of acquired shares until April 14, 2026.

Stakeholder Impact

• Shareholders: Will vote on director elections, auditor ratification, and executive compensation. The virtual meeting format allows for broader participation.
• Employees: Executive compensation is detailed, with performance-based incentives and stock ownership guidelines.
• Directors: Compensation for non-employee directors is outlined, including cash retainers and equity grants. Two directors will conclude their service.

Next Steps

• Stockholders to vote on the election of directors, ratification of auditors, and executive compensation.
• Attend the virtual 2026 Annual Meeting of Stockholders on May 14, 2026.
• The Board will consider the outcome of the advisory vote on executive compensation for future decisions.

Key Dates

Recommendation

This filing is a routine proxy statement for an annual meeting and does not contain new financial performance data or strategic shifts that would warrant a buy or sell recommendation. The information presented is standard for such a filing, including director nominations and executive compensation disclosures.

Keywords

Certara, Proxy Statement, Annual Meeting, Stockholders, Directors, Executive Compensation, RSM US LLP, CEO Transition, Biosimulation, Drug Development